Catheter Precision, Inc.

For the period ended Mar 31, 2026. Filed May 18, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 18, 2026

VTAK$0.15-0.7%Stored close · as of Oct 2, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share data)

Total
Series B Convertible Preferred Stock · Series C-1 Convertible Preferred Stock · Series J Convertible Preferred Stock · Series X Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Catheter Precision Inc. Stockholders' · Non-controlling · Total Stockholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	Equity	Interest	Equity
Balance at December 31, 2025	2,229	$—	—	$—	9,490	$—	—	$—	1,738,955	$—	$316,589	$(309,535)	$7,054	$(403)	$6,651
Issuance of common stock and other equity-classified contracts (see Note 12)	—	—	3,470	—	—	—	—	—	392,608	—	3,731	—	3,731	—	3,731
Issuance of common stock upon exercise of warrants (see Note 12)	—	—	—	—	—	—	—	—	225,564	—	401	—	401	—	401
Conversion of preferred stock	(597)	—	—	—	—	—	—	—	335,346	—	—	—	—	—	—
Stock-based compensation	—	—	—	—	—	—	—	—	—	—	64	—	64	—	64
Net loss	—	—	—	—	—	—	—	—	—	—	—	(1,681)	(1,681)	(9)	(1,690)
Balance at March 31, 2026	1,632	$—	3,470	$—	9,490	$—	—	$—	2,692,473	$—	$320,785	$(311,216)	$9,569	$(412)	$9,157

Total
Series B Convertible Preferred Stock · Series C-1 Convertible Preferred Stock · Series J Convertible Preferred Stock · Series X Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated · Catheter Precision Inc. Stockholders' · Non-controlling · Total Stockholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	Equity	Interest	Equity
Balance at December 31, 2024	—	$—	—	$—	—	$—	12,656	$—	421,296	$—	$304,109	$(292,352)	$11,757	$—	$11,757
Stock-based compensation	—	—	—	—	—	—	—	—	—	—	91	—	91	—	91
Issuance of common stock for vested restricted stock awards	—	—	—	—	—	—	—	—	2,631	—	—	—	—	—	—
Issuance of common stock for asset acquisition (see Note 15)	—	—	—	—	—	—	—	—	14,473	—	113	—	113	—	113
Issuance of common stock upon release of Prepaid Series Warrants (see Note 12)	—	—	—	—	—	—	—	—	49,421	—	—	—	—	—	—
Net loss	—	—	—	—	—	—	—	—	—	—	—	(4,045)	(4,045)	—	(4,045)
Balance at March 31, 2025	—	$—	—	$—	—	$—	12,656	$—	487,821	$—	$304,313	$(296,397)	$7,916	$—	$7,916

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.